Phase 2 N=45 Study Evaluating the Addition of Pembrolizumab to Radium-223 in mCRPC
Prostate Cancer
Primary: Number of Participants With Increased Immune Cell Infiltration Across Arms — 7; 2; 14; 3 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=6 TRACER [F-18] RDG-K5 Carotid Plaque Imaging Study
Carotid Arteries
Primary: Uptake of [F-18] RGD-K5 by Carotid Plaque With PET/MRI Imaging in the Artery Believed to be the Cause of Transient Ischemic Attack (TIA) or Stroke Symptoms Compared to…
Phase 2 N=149 Study to Evaluate the Safety and Efficacy of CTP-543 in Adults With Moderate to Severe Alopecia Areata
Alopecia Areata
Primary: Percentage of Participants Achieving at Least a 50% Relative Reduction in Severity of Alopecia Tool (SALT) Score From Baseline at Week 24 — 9.3; 21.4; 47.4; 58.3…
Phase 2 N=63 Study of TER-101 Topical Ointment in Subjects With Atopic Dermatitis
Atopic Dermatitis
Primary: Percent Change in EASI From Baseline at Day 29 — -47.37; -42.10 percent change
Phase 2 N=56 Phase II Venetoclax, Obinutuzumab and Bendamustine in High Tumor Burden Follicular Lymphoma as Front Line Therapy
Follicular Lymphoma · Non-Hodgkin's Lymphoma Follicular · Non-Hodgkin's Lymphoma, Adult High Grade
Primary: Complete Response (CR) at End of Induction — 41; 11; 1; 0 Participants
Phase 2 N=28 A Study Evaluating the Effects of GLPG3970 Given as an Oral Treatment for 6 Weeks in Adults With Moderately to Severely Active Rheumatoid Arthritis and an Inadequate Response to Methotrexate
Rheumatoid Arthritis
Primary: Change From Baseline in DAS-28 (CRP) at Week 6 — -1.29; -1.24 Score on a scale — p=0.885
Phase 2 N=1,242 A Study of JNJ-70033093 (BMS-986177) Versus Subcutaneous Enoxaparin in Participants Undergoing Elective Total Knee Replacement Surgery
Arthroplasty, Replacement, Knee
Primary: Number of Participants With Total Venous Thromboembolism (VTE) (CEC-adjudicated) — 7; 30; 27; 14 Participants
Phase 2 N=40 Dose-ranging Efficacy and Pharmacokinetics Study of Intravenous Atorvastatin in Hypercholesterolemic Patients
Hypercholesterolemia · Dyslipidemias
Primary: Efficacy, Number of Participants With Day 15 LDL-C Less Than or Equal to 125% of Baseline LDL-C — 9; 9; 1; 7 Participants
Phase 2 N=47 A Study of CRV431 Dosed Once Daily in NASH Induced F2 and F3 Subjects
NASH - Nonalcoholic Steatohepatitis · Fibrosis, Liver · NAFLD - Nonalcoholic Fatty Liver Disease
Primary: Number of Safety and Tolerability Events of CRV431 Versus Placebo. — 4; 8; 3; 21 Number of treatment emergent AE
Phase 2 N=27 Pembrolizumab TX-naive Distant Mets Melanoma and Use of (C11-AMT) PET at Baseline as Imaging Biomarker
Melanoma
Primary: Association of Baseline C11-AMT PET SUV Max Value With Objective Response — 6; 6; 1; 13 Participants — p=0.08
Phase 2 N=20 Romidepsin Plus 3BNC117 Phase 2a Study
Human Immunodeficiency Virus (HIV)
Primary: Days to Viral Rebound During Analytical Treatment Interruption (ATI) — 18; 28 days
Phase 2 N=11 Vyxeos(CPX-351) in Adults w R/R Acute Lymphoblastic Leukemia
Lymphoid Leukemia · Acute Lymphoblastic Leukemia · Refractory Acute Lymphoblastic Leukemia
Primary: Complete Remission Rate (CR) + CR With Incomplete Recovery (CRi) — 30 Percent of participants
Phase 2 N=45 Study of VX-121 in Healthy Subjects and in Subjects With Cystic Fibrosis
Cystic Fibrosis
Primary: Safety and Tolerability as Assessed by Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) — 1; 4; 2; 4 participants
Phase 2 N=84 A Study of SIMPONI® to Arrest Beta-cell Loss in Type 1 Diabetes
Diabetes Mellitus, Type 1
Primary: Active Treatment Period: C-peptide Area Under the Concentration-time Curve (AUC) Calculated From a 4 Hour Mixed Meal Tolerance Test (MMTT) at Week 52 — 0.43; 0.64…
Phase 2 N=119 Seladelpar (MBX-8025) in Subjects With Primary Biliary Cholangitis (PBC)
Primary Biliary Cirrhosis
Primary: Relative Change From Baseline in Serum Alkaline Phosphatase (ALP) at Week 8 — -26.06; -33.38; -41.42 percentage change from baseline — p== 0.2242